Irinotecan Hydrochloride

• Radiation-Sensitizing Agents
• Prodrugs
• Parasympathomimetics
• Antineoplastic Agents
• Enzyme Inhibitors
• ATC:L01XX19

• CP0
• Camptosar
• IRINOTECAN, CPT-11
• Irinotecan Hcl
• Irinotecan Hydrochloride
• Irinotecan Hydrochloride Trihydrate
• Irinotecanum [Inn-Latin]

• No information avaliable

C₃₃H₃₈N₄O₆

http://www.rxlist.com/cgi/generic2/irinot.htm

Irinotecan_Hydrochloride FDA

Irinotecan_Hydrochloride MSDS

T. Miyasaka et al., U.S. pat. 4,604,463 (1985, 1986 both to Yakult Honsha)

586.678 g/mol

222-223 ^oC

Soluble

Solid

4.372

Solution for IM injection

For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin).

Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of Irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either Irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks. The precise contribution of SN-38 to the activity of Irinotecan in humans is not known. Irinotecan is cell cycle phase-specific (S-phase).

100%

Gastrointestinal complications, such as nausea, vomiting, abdominal cramping, diarrhea, and infection.

Humans and other mammals